CTIC Read Out Pacritinib March 2015

Pacritinib

• In December 2014, researchers presented data showing treatment with pacritinib, a next generation oral multikinase inhibitor in Phase 3 development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays. In addition, significant synergy resulted with a combination treatment of pacritinib and cytarabine or a MEK inhibitor. In a separate presentation, researchers showed pacritinib demonstrated a unique kinome profile that supports potential role in modulating tumor microenvironments in blood-related cancers, including AML, myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and chronic lymphocytic leukemia (CLL).